An Overview of Available Preclinical Models for Non-alcoholic Fatty Liver Disease
Posted 13th May 2020 by Liv Sewell
NASH is thought to affect 25% of the global population and is a primary risk factor for Hepatocellular carcinoma (HCC) – the second most common cause of cancer deaths worldwide. Understanding the aetiology of NAFLD progression, developing non-invasive diagnostic tests and developing treatments are urgent priorities.
Hafnia alvei HA4597™ – a new clinically validated solution in weight management
Posted 8th April 2020 by Joshua Sewell
Hyperphagia is a common underlying cause of overweight and obesity. However, the dieting approaches towards weight loss are usually ineffective due to a persistent increase in appetite. Most of the current products in weight management are based on the principle of sugar/fat blockers and binders which has proven to be rather short-term solution.
How does Maternal Microbiome composition influence offspring metabolic outcomes?
Posted 27th February 2019 by Joshua Sewell
Professor Margaret Morris is Chair and Head of Pharmacology, School of Medical Sciences, University of NSW. Her research explores the underlying brain mechanisms in epilepsy, obesity, diabetes, and the link between obesity and high blood pressure. We recently asked her about her research into obesity and the microbiome.
Links Between Obesity and the Gut Microbiome: What do They Mean for Therapeutics?
Posted 24th October 2016 by Jane Williams
Obesity affects 600 million people globally, but the range of available treatments is limited. Recent findings that demonstrate a relationship between the gut microbiome and obesity have brought new hope that bacteria-based therapeutics might offer novel treatments.
